Mirikizumab: Primary completion of P3 VIVID-1 trial (NCT03926130) for Crohn's disease in Feb 2022 (Eli Lilly) - Apr 23, 2020 - Q1 2020 Results: Completion of P3 VIVID-1 trial for Crohn's disease in Jul 2023; Primary completion and completion of P3 VIVID-2 trial (NCT04232553) for Crohn's disease Nov 2023 Trial completion date • Trial primary completion date • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease
|